<i>Glp1r-Lepr</i> coexpressing neurons modulate the suppression of food intake and body weight by a GLP-1/leptin dual agonist
Glucagon-like peptide-1 (GLP-1) and leptin signal recent feeding and long-term energy stores, respectively, and play complementary roles in the modulation of energy balance. Previous work using single-cell techniques in mice revealed the existence of a population of leptin receptor (<i>Lepr</i>)-containing dorsomedial hypothalamus (DMH) neurons marked by the expression of GLP-1 receptor (<i>Glp1r</i>; LepR<sup>Glp1r</sup> neurons) that play important roles in the control of feeding and body weight by leptin. Here, we demonstrate the existence of a population of LepR<sup>Glp1r</sup> neurons in the DMHs of nonhuman primates (NHPs), suggesting the potential translational relevance of these neurons. Consequently, we developed a GLP-1R/LepR dual agonist and demonstrated the physiological activity of both components in vivo using leptin-deficient and <i>Lepr-</i>deficient murine models. We further found roles for LepR<sup>Glp1r</sup> neurons in mediating the dual agonist's efficacy on food intake and body weight loss. Ablating <i>Lepr</i> in <i>Glp1r</i>-expressing neurons (Lepr<sup>Glp1r</sup>KO mice) abrogated the suppression of food intake by the dual agonist. Furthermore, reactivation of <i>Glp1r</i> expression in <i>Lepr</i> neurons on an otherwise <i>Glp1r</i>-null background (Glp1r<sup>Lepr</sup>Re mice) was sufficient to permit the suppression of food intake and body weight by the dual agonist. Hence, LepR<sup>Glp1r</sup> neurons represent targets for a GLP-1R/LepR dual agonist that potently reduces food intake and body weight.
Authors
- Sofia Lundh (ORCID: https://orcid.org/0000-0002-4552-0312)
- Carsten E. Stidsen (ORCID: https://orcid.org/0000-0002-6636-3600)
- I. Jack Magrisso
- Wouter F. J. Hogendorf
- Martin Grosvenor Myers (ORCID: https://orcid.org/0000-0001-9468-2046)
- Stace Kernodle (ORCID: https://orcid.org/0000-0001-7750-8804)
- Joseph Polex-Wolf (ORCID: https://orcid.org/0000-0002-0441-8872)
- Christian W. Tornøe (ORCID: https://orcid.org/0000-0002-6549-1213)
- Randy J. Seeley (ORCID: https://orcid.org/0000-0002-3721-5625)
- S. Sherona Bau (ORCID: https://orcid.org/0000-0002-2873-7974)
- Kristine Deibler (ORCID: https://orcid.org/0000-0002-2376-8456)
- Abigail J. Tomlinson (ORCID: https://orcid.org/0000-0002-4192-9639)
- Kilian W. Conde‐Frieboes (ORCID: https://orcid.org/0000-0001-5303-4448)
- Charles Pyke (ORCID: https://orcid.org/0000-0002-7286-5009)
- Lotte Bjerre Knudsen (ORCID: https://orcid.org/0000-0002-2439-7116)
- Tine Glendorf (ORCID: https://orcid.org/0000-0002-6874-7405)
- Dong Tiantang
Institutions
- Novo Nordisk (Denmark) (DK)
- University of Michigan (US)
- Novo Nordisk (United States) (US)
- Novo Nordisk (Switzerland) (CH)
Publication Details
- Journal
- Science Translational Medicine
- Published
- 2024-12-04
- DOI
- https://doi.org/10.1126/scitranslmed.adk4908
- Citations
- 21
- Primary Topic
- Regulation of Appetite and Obesity
- Type
- article
- Field-Weighted Citation Impact
- 5.75
Funders
- Eli Lilly and Company
- Novo Nordisk
- National Institutes of Health